Matthew A. Marx - Concepedia

Author

Matthew A. Marx

Also Known As

M Marx, M. A. MARX, M. A. Marx, M. Marx, Marie Luisa Marx, Marx, Matthew A., Matt Marx, Matthew A Marx, Matthew A. Marx, Matthew Arnold Marx

159

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Mirati Therapeutics (United States)Array BioPharma (United States)The University of Texas at Austin Neurocrine Biosciences (United States)

About

Matthew A. Marx is an author at Pfizer (United States) specializing in pharmacology, natural sciences, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	15	1.1K
2	Natural Sciences	12	13	712
3	Biochemistry	9	9	464
4	Engineering	3	3	158
5	Biomedical Engineering	1	1	22

Matthew A. Marx

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients Jill Hallin, Lars D. Engstrom, Lauren Hargis, Cancer Discovery	2019	1.2K
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor Xiaolun Wang, Shelley Allen, James F. Blake, Journal of Medicinal Chemistry	2021	644
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer Jay B. Fell, John P. Fischer, Brian R. Baer, Journal of Medicinal Chemistry	2020	559
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor Jill Hallin, Vickie Bowcut, Andrew Calinisan, Nature Medicine MedicinePharmacologyPharmacotherapyAnti-tumor EfficacyAnti-cancer Agent	2022	465
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer Lars D. Engstrom, Ruth Aranda, Laura Waters, Cancer Discovery	2023	163
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i> -Deleted Cancers Christopher R. Smith, Ruth Aranda, Thomas P. Bobinski, Journal of Medicinal Chemistry	2022	139
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Jean S. Beebe, Jitesh P. Jani, Elisabeth Knauth, PubMed Cancer TherapyPharmacological CharacterizationTumor BiologyMolecular PharmacologyAngiogenesis	2003	128
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity Jay B. Fell, John P. Fischer, Brian R. Baer, ACS Medicinal Chemistry Letters	2018	104
Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity Michael J. Munchhof, Jean S. Beebe, Jeffery M. Casavant, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryMedicineVegfr-2 Kinase ActivityPharmacotherapyAnti-cancer Agent	2003	96
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction John M. Ketcham, Jacob R. Haling, Shilpi Khare, Journal of Medicinal Chemistry	2022	87

Page 1